The integration of positron emission tomography (PET) imaging with cerebrospinal fluid (CSF) and blood-based biomarkers represents a cornerstone of modern [Alzheimer's disease](/diseases/alzheimers-disease) (AD) biomarker research. This approach combines the excellent spatial resolution and in vivo pathology visualization of PET with the molecular specificity and sensitivity of fluid biomarkers.
Rationale for Integration
Complementary Information
PET imaging provides:
Regional distribution of amyloid plaques and neurofibrillary [tau](/proteins/tau) tangles
Spatial patterns of glucose hypometabolism
Direct visualization of amyloid and tau pathology in the brain
Fluid biomarkers provide:
Quantitative measures of protein abnormalities in the central nervous system
Dynamic measures that can track disease progression
Information about neurodegeneration through [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)
Clinical Research Applications
The combination enables researchers to:
...
Overview
Mermaid diagram (expand to render)
The integration of positron emission tomography (PET) imaging with cerebrospinal fluid (CSF) and blood-based biomarkers represents a cornerstone of modern [Alzheimer's disease](/diseases/alzheimers-disease) (AD) biomarker research. This approach combines the excellent spatial resolution and in vivo pathology visualization of PET with the molecular specificity and sensitivity of fluid biomarkers.
Rationale for Integration
Complementary Information
PET imaging provides:
Regional distribution of amyloid plaques and neurofibrillary [tau](/proteins/tau) tangles
Spatial patterns of glucose hypometabolism
Direct visualization of amyloid and tau pathology in the brain
Fluid biomarkers provide:
Quantitative measures of protein abnormalities in the central nervous system
Dynamic measures that can track disease progression
Information about neurodegeneration through [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL)
Clinical Research Applications
The combination enables researchers to:
Validate biomarker equivalence - Confirm that fluid biomarkers accurately reflect brain pathology visible on PET
Understand temporal sequences - Map the order in which biomarker abnormalities occur
Improve diagnostic accuracy - Combine imaging and fluid data for more precise diagnoses
Enrich clinical trials - Use biomarker combinations to identify optimal patient populations
Key Research Findings
Amyloid PET + CSF Biomarkers
Studies presented at AAIC 2026 demonstrated:
High concordance between amyloid PET positivity and CSF [Aβ42](/proteins/amyloid-beta)/40 ratio (85-95% agreement)
Discordance patterns provide biological insights - some individuals with positive PET have normal CSF and vice versa
CSF Aβ42/40 as a reliable screening tool to identify amyloid-positive individuals for PET imaging
Tau PET + CSF p-tau Biomarkers
The relationship between tau PET and CSF phosphorylated tau (p-tau) was a major focus:
Strong correlation between regional tau PET uptake and CSF p-tau181/p-tau217 levels
[p-tau217](/biomarkers/p-tau-217) shows particularly high correlation with tau PET in neocortical regions
Regional specificity - CSF p-tau may detect earlier tau changes than PET
Neurodegeneration Markers
Integration of imaging and fluid biomarkers for neurodegeneration:
MRI atrophy patterns combined with NfL provide complementary information
FDG-PET hypometabolism correlates with CSF NfL in advanced disease
Multimodal markers improve prediction of cognitive decline
AT(N) Classification System
The NIA-AA Research Framework uses biomarker categories[@jack2018]:
| Category | Imaging Biomarkers | Fluid Biomarkers | |----------|-------------------|------------------| | A (Amyloid) | Amyloid PET | CSF Aβ42/40, Aβ42 | | T (Tau) | Tau PET | CSF p-tau181, p-tau217 | | (N) (Neurodegeneration) | MRI, FDG-PET | CSF/serum NfL, t-tau |
Clinical Profiles
| Profile | Amyloid | Tau | Neurodegeneration | |---------|---------|-----|-------------------| | AD | + | + | + | | AD path, no neurodegeneration | + | + | - | | Non-AD pathologic change | - | + or - | + |
Implementation Considerations
Cost-Effectiveness Strategies
Use CSF screening to reduce unnecessary PET scans
Sequential testing strategies for clinical diagnosis
Blood-based biomarkers as initial screening tools
Technical Harmonization
Standardization of CSF assays across laboratories
PET quantification harmonization (e.g., Centiloid project)
[Amyloid PET](/biomarkers/amyloid-pet) - under development
[CSF Aβ42](/biomarkers/amyloid-beta-42-csf) - under development
[p-tau181](/biomarkers/p-tau181) - under development
[p-tau217](/biomarkers/p-tau217) - under development
[Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl) - under development
References
[Jack CR Jr, et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)
[Hansson O, et al., The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022 (2022)](https://doi.org/10.1002/alz.12756)
[Palmqvist S, et al., Detailed comparison of amyloid PET and CSF biomarker abnormalities in Alzheimer disease. Neurol Genet. 2021 (2021)](https://doi.org/10.1212/NXG.0000000000000553)